Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Retension Pharmaceuticals, Inc. (RTSN)

Retension Pharmaceuticals names Robert Wong chief accounting officer, effective Nov. 2, 2026

Neutral Impact 2 of 5 leadership Written later

Retension Pharmaceuticals, Inc. appointed Robert Wong as Vice President and Chief Accounting Officer, effective November 2, 2026, according to an 8-K filed October 22, 2026. The filing describes his prior accounting and controllership roles and his offer letter terms, which include a $360,000 base salary and a 25,000-share stock option award.

Key points

  • Appointed by the Board on October 21, 2026, effective November 2, 2026, as principal accounting officer
  • Annual base salary of $360,000 with a discretionary bonus target of 30% of base salary, prorated for 2026
  • Sign-on bonus of $20,000, subject to continued employment through March 31, 2027
  • Stock option to buy 25,000 shares, vesting 25% on the first anniversary of the start date, then monthly over 36 months

The filing

CompanyRetension Pharmaceuticals, Inc. (RTSN)
Form8-K, current report
Filed with the SECOct 22, 2026, 7:33 PM ET
Accession number0001213900-26-111794

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.